Monica Bertagnolli, NIH’s New Leader, Wants to Broaden Participation in Medical Research

Omalizumab, a recombinant humanized IgG1 monoclonal antibody, reduces allergic reactions to multiple foods in NIH trial. This could expand the amount of different common foods that children with food allergies can safely consume without eliciting an allergic reaction.

Once reluctant, new NIH chief Monica Bertagnolli has embraced her leading role

NIH advisory group recommends $14,000 boost in postdoc pay